An interventional study of PKU Explore in Phenylketonuria and Inborn Errors of Metabolism, sponsored by Vitaflo International, Ltd. Completed at 3 sites in United Kingdom. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2024-02-16.
Sponsored by Vitaflo International, Ltd · Not applicable, Interventional, and Treatment
To evaluate the acceptability, tolerance and effect on metabolic control of PKU Explore, a renovated Phe free protein substitute for the dietary management of PKU in children from 6 months to 5 years.
This is a prospective, acceptability study to evaluate the gastrointestinal tolerance, palatability and adherence of PKU explore in a four-week period for 15 participants aged between 6 months and 5 years for the dietary management of PKU.
The outcome of this assessment will be used in a submission to the regulatory authorities, Advisory Committee on Borderline Substances (ACBS), for PKU Start to become reimbursable on prescription in the UK.
The participant's dietitian will advise on an appropriate amount of PKU Explore based on individual requirements. Parents/carers will be asked to substitute their usual Phe-free protein substitute with PKU Explore for one (1) month. The sponsor will supply PKU Explore free of charge.
Parents/guardians will be asked to record information about the following:
Daily PKU Explore intake Stools Vomiting and Spit-up Feed / Fluid Intake Compliance Phenylalanine Levels (from their routine blood spot testing)
Final Evaluation about the presentation of the product, ease of preparation and use.
i. A diagnosis of PKU on new-born screening requiring a low protein diet and Phe-free L-amino acid supplements.
ii. Aged between 6 months and 5 years.
iii. Already taking a second stage concentrated protein substitute as part of their PKU management OR is at the stage in their PKU management when a second stage concentrated protein substitute is recommended to commence.
iv. Willingly given, written, informed consent from parent/guardian.
v. Willingly given, written assent (if appropriate).
Exclusion Criteria:
i. Diagnosis of persistent hyperphenylalaninaemia, or mild PKU not requiring dietary treatment with a low protein diet and Phe-free L-amino acid supplements.
ii. Diagnosis of a concurrent condition which may adversely affect developmental progression and feeding ability.
iii. Participation in any other clinical trial/acceptability study.
iv. Any serious medical precluding the study intervention.
v. Use of additional macro/micronutrient supplements during the study period, unless clinically indicated and prescribed by the investigator (must be recorded in patient case record file).
Daily feed, substituting the participant's normal phe-free protein substitute for PKU Explore.
Dietary Supplement: PKU Explore
PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
Product compliance daily diary
Quantitative assessments from subject questionnaires that allow evaluation of compliance with the study product, i.e. actual versus prescribed intake.
Time frame: Days 1-28
GI tolerance daily diary assessing change
Qualitative assessments from subject questionnaires that allow evaluation of any change in the gastro-intestinal tolerance of the study product.
Time frame: Days 1-7 and 22-28
Ease of use questionnaire
Qualitative assessment from subject questionnaire that allows evaluation of the ease of use of the study product.
Time frame: Day 29
Weekly phenylalanine control
Collection of quantitative data regarding phenylalanine control using routine biochemical testing
Time frame: Days 1-28
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vitaflo International, Ltd